Chromadex Corp Stock Price, News & Analysis

ChromaDex Corp. (NASDAQ:CDXC) partners with MyPharma2Go to introduce Tru Niagen® to Brazil, the first Latin American market for the product. This partnership enables cross-border sales of Tru Niagen® and Tru Niagen® PRO, which are based on the key ingredient nicotinamide riboside (NR), a leading NAD+ precursor. Both products are now available through Brazilian e-commerce platforms. With a track record of reaching over 240,000 patients, MyPharma2Go aims to enhance access to these supplements for healthy aging, supported by extensive clinical research backing Niagen®.

Ayana Bio has appointed Frank Jaksch as CEO, a veteran in the health and wellness industry, particularly known for founding ChromaDex, which develops the NAD product Tru Niagen (Nasdaq: CDXC). Launched in September 2021, Ayana Bio utilizes innovative plant cell technology to produce sustainable bioactives for consumer products, aiming to address challenges in ingredient supply chains exacerbated by climate change and geopolitical issues. The company, supported by Ginkgo Bioworks (NYSE: DNA), is positioned to revolutionize sourcing through standardized cultivation methods.

ChromaDex Corp. (NASDAQ: CDXC) announced a significant legal victory as the U.S. Patent Trial and Appeal Board rejected Thorne Research's attempt to invalidate U.S. Patent No. 8,197,807, exclusively licensed for compositions containing nicotinamide riboside (NR). This decision strengthens ChromaDex's position in a patent infringement lawsuit against Thorne Research. The company is known for its flagship ingredient, Niagen®, which is backed by extensive clinical research and approved by leading global regulatory agencies.

ChromaDex Corp. (NASDAQ:CDXC) reported Q2 2022 net sales of $16.7 million, a 5% decline year-over-year, primarily due to reduced shipments and lower sales from A.S. Watson impacted by COVID-19. Costs were managed effectively, with gross margin at 60%, despite inflationary pressures. A decrease in general and administrative expenses by $2 million is positive. The company's full-year outlook anticipates high single-digit revenue growth, a consistent gross margin, and a target to achieve cash flow break-even by Q4 2022, supported by e-commerce growth.

ChromaDex Corp. (NASDAQ:CDXC) will hold a conference call on August 10, 2022, at 4:30 p.m. ET, to discuss its second-quarter financial results for the period ending June 30, 2022. A press release detailing the financial results will be issued after market close on the same day.

Investors can participate by calling 1-888-330-2446 with Conference ID 4126168, or join the webcast via ChromaDex's website. A replay will be available starting 7:30 p.m. ET on August 10 until 11:59 p.m. ET on August 17, 2022.

ChromaDex Corp. (NASDAQ:CDXC) will host a webinar on July 20, 2022, at 11:00 am ET featuring Dr. Charles Brenner, a leading expert on nicotinamide adenine dinucleotide (NAD). The session will cover the benefits of nicotinamide riboside (NR) and its role in boosting NAD levels, essential for metabolic processes and cellular repair.Tru Niagen®, ChromaDex's flagship supplement, will also be highlighted. A live Q&A session will follow, and registration is open to the public.

ChromaDex (NASDAQ: CDXC) is enhancing awareness of its research at key conferences, including ASN Nutrition 2022, ISSN, and FASEB’s NAD+ Metabolism and Signaling Conference. The company’s CERP™ program has over 250 material transfer agreements with 235 scientists across 182 institutions. During ASN, presentations will cover topics like NAD+ impact on immune function and cognition. ChromaDex’s involvement aims to highlight the importance of nicotinamide riboside, a precursor to NAD+, for healthy aging and athletic performance.

ChromaDex Corp. (NASDAQ: CDXC) has signed a distribution agreement with Sinopharm Xingsha to enhance cross-border sales of Tru Niagen in China. This partnership aims to amplify brand awareness and secure Health Food Registration in the region, as part of their recent Joint Venture. Currently valued at $700 million in annual sales, the NAD+ supplement market in China is projected to exceed $1.5 billion by 2024. Tru Niagen is backed by scientific research and regulatory approvals across various regions, positioning ChromaDex to capitalize on China's aging population.

ChromaDex Corp. (NASDAQ:CDXC) has announced that CEO Rob Fried and CFO Kevin Farr will present at Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference on June 15 at 3:45 p.m. Eastern Time. The presentation will be virtual, and the management team will also engage in one-on-one meetings with institutional investors throughout the day. ChromaDex is committed to healthy aging, focusing on research related to nicotinamide adenine dinucleotide (NAD+) and its precursor, nicotinamide riboside (NR), marketed as Niagen®.